Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
211 - Since Jan 2009 Q&A, is there update further to question #84 on distribution of reprints and Health Canada/PAAB postiion?
-
The answer to question #84 has not changed. Health Canada is ever vigilant of off-label promotion and unsolicited distribution of reprints by pharma reps is a tactic that can do that. Therefore, the PAAB advises companies to train their reps well and restrict the materials they hand out, to those that meet the requirements of the federal law and the PAAB Code of Advertising Acceptance.
